Since the introduction of Sovaldi (sofosbuvir) in September 2014 — at a cost of about $84,000 for the full 12-week course of treatment — other highly curative but expensive hepatitis C virus (HCV) treatments, known as direct-acting antiviral drugs, have proliferated in the U.S. market. Yet research released last June by the University of Pennsylvania School of Medicine, disputed as misleading by America’s Health Insurance Plans (AHIP), indicates that private insurers denied such coverage for 52.4% of patients, while Medicaid denied 34.5% and Medicare, 14.7%, between January 2016 and April 2017.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.